$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000114420416091632 Filed on March 30, 2016

Income Statement

Concept	2016 Q1	2014 Q4	2014
Revenue	$1.215M	$1.400M	$4.787M
YoY Change	-32.04%	180.0%	851.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.080M	$680.0K	$3.020M
YoY Change	-22.86%	-47.69%	36.65%
% of Gross Profit
Research & Development	$4.341M	$2.580M	$7.787M
YoY Change	14.03%	-49.11%	49.84%
% of Gross Profit
Depreciation & Amortization	$31.60K	$10.00K	$41.90K
YoY Change	27.43%	-66.67%	55.61%
% of Gross Profit
Operating Expenses	$5.426M	$3.270M	$10.80M
YoY Change	4.29%	-48.67%	45.89%
Operating Profit	-$4.211M		-$6.018M
YoY Change	23.31%		-12.82%
Interest Expense	$66.13K	-$60.00K	$200.5K
YoY Change	7.2%	500.0%	244.9%
% of Operating Profit
Other Income/Expense, Net	-$55.62K		-$198.6K
YoY Change	-9.43%		-90.01%
Pretax Income	-$4.270M	-$1.930M	-$6.220M
YoY Change	22.7%	-74.13%	-30.03%
Income Tax
% Of Pretax Income
Net Earnings	-$4.266M	-$1.930M	-$6.217M
YoY Change	22.73%	-74.13%	-30.09%
Net Earnings / Revenue	-351.11%	-137.86%	-129.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.588M	-$1.650M	-$5.316M
COMMON SHARES
Basic Shares Outstanding	17.95M shares	11.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2014 Q4	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.26M	$8.030M	$8.030M
YoY Change	-36.38%	290.56%	289.81%
Cash & Equivalents	$11.77M	$8.035M	$8.030M
Short-Term Investments	$2.498M	$0.00	$0.00
Other Short-Term Assets	$320.0K	$3.220M	$3.220M
YoY Change	-85.78%	98.77%	98.77%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.89M	$11.61M	$11.61M
YoY Change	-41.42%	215.35%	215.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$345.0K	$229.5K	$230.0K
YoY Change	37.98%	209.29%	228.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$70.00K	$60.00K	$60.00K
YoY Change	0.0%	100.0%	100.0%
Total Long-Term Assets	$2.095M	$2.025M	$2.020M
YoY Change	2.2%	9.02%	8.6%
TOTAL ASSETS
Total Short-Term Assets	$14.89M	$11.61M	$11.61M
Total Long-Term Assets	$2.095M	$2.025M	$2.020M
Total Assets	$16.98M	$13.63M	$13.63M
YoY Change	-38.17%	146.16%	146.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.690M	$2.130M	$2.130M
YoY Change	9.17%	3.9%	3.9%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.341M	$6.300M	$6.300M
YoY Change	-2.71%	206.86%	207.32%
LONG-TERM LIABILITIES
Long-Term Debt	$10.16M	$9.160M	$9.160M
YoY Change	10.92%	131.31%	131.31%
Other Long-Term Liabilities	$570.0K	$4.430M	$4.430M
YoY Change	-83.48%	7283.33%	7283.33%
Total Long-Term Liabilities	$10.73M	$13.58M	$13.59M
YoY Change	-14.87%	237.85%	238.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.341M	$6.300M	$6.300M
Total Long-Term Liabilities	$10.73M	$13.58M	$13.59M
Total Liabilities	$18.07M	$19.88M	$19.88M
YoY Change	-10.32%	227.38%	227.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.44M	-$22.32M
YoY Change	52.92%	38.62%
Common Stock	$38.33M	$16.07M
YoY Change	15.75%	3.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.083M	-$6.249M	-$6.250M
YoY Change
Total Liabilities & Shareholders Equity	$16.98M	$13.63M	$13.63M
YoY Change	-38.17%	146.16%	146.03%

Cashflow Statement

Concept	2016 Q1	2014 Q4	2014
OPERATING ACTIVITIES
Net Income	-$4.266M	-$1.930M	-$6.217M
YoY Change	22.73%	-74.13%	-30.09%
Depreciation, Depletion And Amortization	$31.60K	$10.00K	$41.90K
YoY Change	27.43%	-66.67%	55.61%
Cash From Operating Activities	-$4.180M	-$2.140M	$960.0K
YoY Change	103.9%	-62.98%	-115.64%
INVESTING ACTIVITIES
Capital Expenditures	$45.81K	$40.00K	$162.7K
YoY Change	66.85%	-136.36%	189.92%
Acquisitions
YoY Change
Other Investing Activities	$5.490M	$330.0K	$0.00
YoY Change		-91.52%	-100.0%
Cash From Investing Activities	$5.450M	$370.0K	$140.0K
YoY Change	-135.12%	-90.21%	-96.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.930M	0.000	5.210M
YoY Change	-70.08%	-100.0%	32.57%
NET CHANGE
Cash From Operating Activities	-4.180M	-2.140M	960.0K
Cash From Investing Activities	5.450M	370.0K	140.0K
Cash From Financing Activities	4.930M	0.000	5.210M
Net Change In Cash	6.200M	-1.770M	6.310M
YoY Change	-668.81%	-214.19%	301.91%
FREE CASH FLOW
Cash From Operating Activities	-$4.180M	-$2.140M	$960.0K
Capital Expenditures	$45.81K	$40.00K	$162.7K
Free Cash Flow	-$4.226M	-$2.180M	$797.3K
YoY Change	103.41%	-61.55%	-112.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-12857339	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	980	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2977024	USD
CY2015	capr	Collaboration Revenue CollaborationRevenue	3776041	USD
CY2014	capr	Collaboration Revenue CollaborationRevenue	4166667	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	620033	USD
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	1741607	USD
CY2014	us-gaap	Revenues Revenues	4786700	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3017301	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4372195	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	10804685	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	18129474	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-6017985	USD
CY2014	us-gaap	Interest Expense InterestExpense	200505	USD
CY2015	us-gaap	Interest Expense InterestExpense	248626	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-198607	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-245513	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6215612	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12847954	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11696980	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15902133	shares
CY2014Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	360233	USD
CY2015Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	211938	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	235523	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	210603	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	11607545	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	13600000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229455	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	318566	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	239752	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	191003	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22315127	USD
CY2015	us-gaap	Revenues Revenues	5517648	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7787384	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	13989857	USD
CY2014Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2015Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	55320	USD
CY2015Q4	us-gaap	Other Assets OtherAssets	70146	USD
CY2014Q4	us-gaap	Assets Assets	13632072	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1699254	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2530500	USD
CY2014Q4	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	433712	USD
CY2015Q4	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	352334	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4166667	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3645834	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6299633	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6528668	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4166666	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	911458	USD
CY2014Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2015Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2014Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	258639	USD
CY2015Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	505363	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13581162	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10572678	USD
CY2014Q4	us-gaap	Liabilities Liabilities	19880795	USD
CY2015Q4	us-gaap	Liabilities Liabilities	17101346	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16054697	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	34115052	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9385	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-6248723	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13632072	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	16255	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11707	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-35172466	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13757279	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-12611826	USD
CY2014	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1898	USD
CY2015	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	3113	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-6216592	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9385	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16446218	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	45461	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1573224	USD
CY2014	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	12573	USD
CY2015	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-24920	USD
CY2014	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	29592	USD
CY2015	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	14826	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	70329	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	831246	USD
CY2014	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	9715	USD
CY2015	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-81378	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	200505	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	246724	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10817286	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	17989625	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	327474	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10000000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	162687	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	129697	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	141043	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8140852	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5205623	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16491679	USD
CY2015	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	-148295	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3776041	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	958562	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2014	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16446218	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	8333333	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1729537	USD
CY2015	us-gaap	Interest Paid InterestPaid	2685	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	23744	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6305228	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41896	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	110865	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	496939	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1573224	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	1575165	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-2977024	USD
CY2014	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	360233	USD
CY2014	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4832	USD
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2014Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	8000000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16254985	shares
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4832	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-534882	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	496939	USD
CY2015	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	21530	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2466459	USD
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	45461	USD
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5200791	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2839045	shares
CY2015Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.523
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1658822	shares
CY2015Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.25
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7050000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	48749	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	48749	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	43733	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	43277	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4330	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2165	USD
CY2015	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1500000	USD
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	7999010	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	30000	USD
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16254985	shares
CY2015	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	52650	shares
CY2015	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	47.00
CY2015	capr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	15401	shares
CY2015	capr	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	2.27
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.27
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	235830	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	332281	shares
CY2014	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	28400	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.20
CY2014	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	94.00
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.02
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	303881	shares
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1564635	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	480237	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.40
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4200000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2015Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	13600000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	17957	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	364866	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	96750	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	461616	USD
CY2015	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
CY2013Q4	capr	Additional Milestone Payments To Be Received Contingent Upon Exercise Of Options AdditionalMilestonePaymentsToBeReceivedContingentUponExerciseOfOptions	325000000	USD
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Entity Registrant Name EntityRegistrantName	CAPRICOR THERAPEUTICS, INC.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001133869
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q2	dei	Entity Public Float EntityPublicFloat	32449891	USD
CY2015	dei	Trading Symbol TradingSymbol	CAPR
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17952323	shares
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	98679	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	49930	USD
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11707051	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11707051	shares
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the period over which the collaboration revenue is recognized and the stock-based compensation. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5997323	shares
CY2015	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y11M19D
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.59
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	4512802	shares
CY2015	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y4M13D
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.78
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	131708	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	82058	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	492274	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	341047	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	173708	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	111592	USD
CY2015	us-gaap	Depreciation Depreciation	62116	USD
CY2014	us-gaap	Depreciation Depreciation	32163	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	48749	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10733	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022	pure
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6233153	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5308581	shares

Files In Submission

Name	View Source	Status
0001144204-16-091632-index-headers.html	Edgar Link	pending
0001144204-16-091632-index.html	Edgar Link	pending
0001144204-16-091632.txt	Edgar Link	pending
0001144204-16-091632-xbrl.zip	Edgar Link	pending
capr-20151231.xml	Edgar Link	completed
capr-20151231.xsd	Edgar Link	pending
capr-20151231_cal.xml	Edgar Link	unprocessable
capr-20151231_def.xml	Edgar Link	unprocessable
capr-20151231_lab.xml	Edgar Link	unprocessable
capr-20151231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v433695_10k.htm	Edgar Link	pending
v433695_ex10-59.htm	Edgar Link	pending
v433695_ex21-1.htm	Edgar Link	pending
v433695_ex23-1.htm	Edgar Link	pending
v433695_ex31-1.htm	Edgar Link	pending
v433695_ex31-2.htm	Edgar Link	pending
v433695_ex32-1.htm	Edgar Link	pending
v433695_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2016 Q1 Form 10-K Financial Statement

#000114420416091632 Filed on March 30, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2016 Q1 Form 10-K Financial Statement

#000114420416091632 Filed on March 30, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr